| ￥1980 在线订购包邮(港澳台除外) | |
| A02271-40 | |
|
|
|
|
|
|
|
|
|
| 咨询产品问题 | |
| Specificity | This product is specific for Lecanemab. |
| Host Species | Rabbit |
| Immunogen | Lecanemab |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||||||
|
|||||||||
| Form | Lyophilized |
| Storage Buffer | Lyophilized with PBS, pH 7.2, containing 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for 1 year at -20℃ from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8℃ or for 12 months at -20℃ or below. Avoid repeated freezing and thawing cycles. |
| Purification | Protein A affinity column |
| Isotype | Rabbit IgG, κ |
| Clonality | Monoclonal |
| Clone ID | 4F2 |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
»
BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ Anti-Lecanemab Antibody (4F2), mAb, Rabbit (GenScript, A02271) to Lecanemab.
Lecanemab captured on HFC (Anti-Human IgG Fc) Probes can bind MonoRab™ Anti-Lecanemab Antibody (4F2), mAb, Rabbit with a dissociation constant (KD) of less than 1 pM. »
Anti-Lecanemab Antibody (44G1) or (4F2) inhibits the binding of Lecanemab to β-Amyloid (1-42).
Coating antigen: β-Amyloid (1-42), human (GenScript, RP10017) 1 µg/ml.
Lecanemab final concentration: 10 µg/ml.
Anti-Lecanemab antibody dilutions start from 10 μg/ml.
MonoRab™ Anti-Lecanemab Antibody (44G1), mAb, Rabbit (GenScript, A02270) and MonoRab™ Anti-Lecanemab Antibody (4F2), mAb, Rabbit (GenScript, A02271) demonstrated inhibitory properties. »
Standard Curve of Lecanemab Sandwich ELISA by A02270 (44G1) and A02271 (4F2)
In this Sandwich ELISA assay, MonoRab™ Anti-Lecanemab Antibody (44G1), mAb, Rabbit (GenScript, A02270) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Lecanemab Antibody (4F2), mAb, Rabbit (GenScript, A02271) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/mL. GenScript can provide customized conjugation service for this product per customer's request.
In this assay, a four-parameter logistic curve fitting program was used to create a standard curve with the R-Square equal to 0.99971. The typicaldynamic range of the assay is 0.31 - 20 ng/mL and its detection limit is 0.31 ng/mL. »
MRD Analysis of the Detection of Lecanemab in Biological Matrix.
The MRD is the minimum dilution necessary for the detection of Lecanemab in biological matrix with least interference. Serum samples from cynomolgus monkey were serially diluted to determine the MRD of this assay, and the test result suggested that MRD was as 1:10.
In this ELISA assay, MonoRab™ Anti-Lecanemab Antibody (44G1), mAb, Rabbit (GenScript, A02270) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Lecanemab Antibody (4F2), mAb, Rabbit (GenScript, A02271) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/mL. »
Specificity analysis of the detection of Lecanemab.
Lecanemab samples at 8 concentrations were spiked with 200 ng/mL of human IgG1. The test result demonstrated that the high concentration of human IgG1 did not interfere with the detection of Lecanemab.
In this ELISA assay, MonoRab™ Anti-Lecanemab Antibody (44G1), mAb, Rabbit (GenScript, A02270) was coated at a concentration of 1 μg/ml, and MonoRab™ Anti-Lecanemab Antibody (4F2), mAb, Rabbit (GenScript, A02271) conjugated with Biotin was used as a detection antibody at a concentration of 0.5 μg/mL. »
| Target Background | Lecanemab, marketed as Leqembi, is a medication that is prescribed to treat Alzheimer's disease. Lecanemab is a monoclonal antibody derived from a mouse antibody called mAb158, which has been humanized to improve its compatibility with humans. It specifically targets amyloid beta, a protein associated with the disease. |
| Synonyms | Lecanemab; Leqembi; Lecanemab-irmb; BAN2401; mAb158; Anti-amyloid beta antibody |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
